

Edgar Filing: AETERNA LABORATORIES INC - Form 6-K

AETERNA LABORATORIES INC  
Form 6-K  
February 21, 2003

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For the month of February 2003

AETERNA LABORATORIES INC.

-----  
(Translation of registrant's name into English)

1405, boul. du Parc-Technologique  
Quebec, Quebec  
Canada, G1P 4P5

-----  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports  
under cover of Form 20-F or Form 40-F.

Form 20-F                      Form 40-F    X  
      -----                      -----

Indicate by check mark whether the registrant by furnishing the information  
contained in this Form is also thereby furnishing the information to the  
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934

Yes                                      No    X  
      -----                                      -----

If "Yes" is marked, indicate below the file number assigned to the registrant in  
connection with Rule 12g3-2(b): 82-

-----

DOCUMENTS INDEX

DOCUMENTS DESCRIPTION

- 
- |    |   |
|----|---|
| 1. | Press Release of February 20, 2003: AEterna Reports<br>Financial Results for 2002 |
|----|---|
-

# Edgar Filing: AETERNA LABORATORIES INC - Form 6-K

[AETERNA LOGO OMITTED]

PRESS RELEASE  
FOR IMMEDIATE RELEASE

## AETERNA REPORTS FINANCIAL RESULTS FOR 2002

Year marked by record sales and net earnings  
for its subsidiary Atrium and acquisition of Zentaris AG

ALL FIGURES ARE EXPRESSED IN CANADIAN DOLLARS

QUEBEC CITY, CANADA, FEBRUARY 20, 2003 - AETerna Laboratories Inc. (TSX: AEL, NASDAQ: AELA) reported record revenues of \$101 million for the year ended December 31, 2002, and a net loss of \$25.8 million, or \$0.67 per share, compared to revenues of \$44 million and a net loss of \$3.5 million or \$0.11 per share, for the same period in 2001. The consolidated EBITDA (before non-controlling interest) of its subsidiary Atrium increased 84%, from \$6.9 million to \$12.7 million for 2002. Consolidated net earnings of Atrium increased by 48%, reaching \$6.6 million compared to \$4.5 million, for the same period last year. 2002 highlights include AETerna's acquisition of German biopharmaceutical Zentaris AG for \$85 million, a strategic alliance with Australian Mayne Pharma for the commercialization of Neovastat, and a \$57 million private placement.

### ATRIUM BIOTECHNOLOGIES SELECTED FINANCIAL INFORMATION

(in thousands of Canadian dollars)	12 months ended Dec. 31			3 months ended Dec. 31		
	2002	2001	%	2002	2001	%
Sales	100.9	43.8	130	27.7	20.2	3
EBITDA (before non-controlling interest)	12.7	6.9	84	3.2	2.0	6
Net earnings	6.6	4.5	48	1.6	1.1	3

"In 2002, we surpassed our stated expectations and met our strategic goals," said Gilles Gagnon, President and CEO at AETerna. "The recent acquisition of Zentaris brings added value to our shareholders, providing the Company with an extensive pipeline of 11 new products in high potential markets in oncology and endocrinology, an important network of eight new pharmaceutical partners worldwide, and a self-funded unit managed by high level pharmaceutical experts. Neovastat, our lead antiangiogenic compound, is our top priority in oncology for 2003. Positive results of our Phase III trial in renal cell carcinoma with Neovastat could enable AETerna to open this new class of drugs for the treatment of kidney cancer".

Revenues for 2002 were generated by Atrium whose sales increased by 130% in comparison to 2001. This increase is largely attributable to the acquisition, in July 2001, of the French subsidiary, Unipex. On a proforma basis, Atrium would have registered an

## Edgar Filing: AETERNA LABORATORIES INC - Form 6-K

increase of 36%, taking into account the sales of Unipex for the twelve-month period in 2001. Atrium fourth quarter sales rose \$7.5 million, reaching \$27.7 million compared to \$20.2 million for the same period last year, an increase of 37%. This continued growth reflects the successful integration of Unipex and ADF Chimie, as well as the focused sales strategy.

AEterna's R&D investments increased to \$26.1 million in 2002, in line with targeted figures, compared to \$22.7 million in 2001. This increase allowed the Phase III pivotal clinical trials for the treatment of lung and kidney cancer to continue as planned.

During the fourth quarter, AEterna's R&D investments amounted to \$7.8 million, an increase of \$1.6 million compared to the same period last year. The follow-up of patients enrolled in these trials, as well as the costs incurred for the preparation of Neovastat's Basic International Registration dossier, are principally responsible for the increase in R&D investments.

AEterna recorded a net loss of \$8 million, or \$0.20 per share, in the fourth quarter, compared to a net loss of \$2.8 million or \$0.08 per share for the same period last year. This increased loss is mainly due to future income tax recovery recorded during the last quarter of 2001.

Net loss for the current year was \$25.8 million or \$0.67 per share in comparison with \$3.5 million or \$0.11 per share in 2001. This increase of \$22.3 million is due mostly to future income tax recovery and gain on dilution recorded in 2001, amounting to \$18.9 million, while the balance of \$3.4 million results principally from the increase of R&D investments net from related grants.

As of December 31, 2002, the Company's consolidated cash and short-term investments position was \$81.5 million. Of that amount, \$43 million was used in January 2003 for the acquisition of Zentaris, leaving AEterna with a consolidated cash position of \$38.5 million at the beginning of the current year.

"With \$38.5 million in cash and short-term investments, at the beginning of the current year, we continue to have a solid financial position, especially when considering the fast growth of Atrium, Zentaris' self-funded drug development program, as well as Neovastat's continued controlled burn rate and high market potential," concluded Dennis Turpin, Vice President and Chief Financial Officer at AEterna.

### 2002 HIGHLIGHTS

- April: \$57 million private placement in AEterna for the acquisition program, the development of Neovastat Phase III trials in lung and kidney cancer, as well as general corporate purposes
- May: Atrium acquires French company ADF Chimie S/A, a distributor of active and specialty ingredients to some 50 clients in the French cosmetics industry, including L'Oreal, LVMH and Chanel
- October: AEterna signs strategic partnership agreement with Australia's Mayne Pharma, for marketing Neovastat in Canada, Mexico and Australia
- FDA grants Neovastat Orphan-drug Status for the treatment of renal cell carcinoma, a form of kidney cancer

## Edgar Filing: AETERNA LABORATORIES INC - Form 6-K

December: AETerna acquires German biopharmaceutical Zentaris AG for \$85 million. The transaction provides AETerna with a combined pipeline of 12 products, focusing on oncology and endocrinology

### SCIENTIFIC ARTICLES

During 2002, six scientific articles on Neovastat were published in peer review publications, namely on its multiple mechanisms of action and Phase I/II trial results in lung and kidney cancer. Four others are currently in press. Through the years, hundreds of articles have also been published in influential peer reviews on Zentaris' scientific and clinical research activities.

### PATENTS

In 2002, AETerna obtained two additional patents from the United States Patent and Trademark Organization for broader coverage of Neovastat's manufacturing process as well as a composition including administration of Neovastat in combination with an anticancer agent. Furthermore, two patents were validated by the European Patent Bureau that cover Neovastat and its manufacturing process. AETerna now has nine American patents for Neovastat and five others are pending approval.

With the recent acquisition of Zentaris, the combined entities account for over 70 families of patents at the international level.

### ABOUT AETERNA LABORATORIES INC.

AETerna is a biopharmaceutical company focused on the development of novel therapeutic treatments, mainly in oncology and endocrinology. The product pipeline includes 12 products ranging from preclinical stage up to commercialization. AETerna has strategic worldwide partners such as Access Oncology, Ardana Bioscience, Baxter Healthcare S.A., Grupo Ferrer, Hainan Tianwang International Pharmaceutical, Mayne Group, Medac GmbH, Nippon Kayaku, Sero International S.A., Shionogi & Co., Ltd. and Solvay Pharmaceuticals B.V.

AETerna owns 100% of the biopharmaceutical company, Zentaris AG, based in Frankfurt, Germany.

AETerna also owns 61.8% of Atrium Biotechnologies Inc., which develops and markets nutritional supplements, as well as active ingredients and fine chemicals intended for the cosmetics, nutritional, fine chemical and pharmaceutical industries. Atrium markets over 500 products in 20 countries to industry leaders such as Estee Lauder, L'Oreal, Clarins, Chanel, Aventis, SanofiSynthelabo and Nestle.

AETerna and its entities have 270 employees in Canada and Europe.

AETerna shares are listed on the Toronto Stock Exchange (AEL) and the NASDAQ National Market (AELA).

News releases and additional information about AETerna are available on its Web site at [www.aeterna.com](http://www.aeterna.com)

### SAFE HARBOR STATEMENT

This press release contains forward-looking statements, which are made pursuant

## Edgar Filing: AETERNA LABORATORIES INC - Form 6-K

to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of the business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's ongoing quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements.

- 30 -

### CANADA

#### Media Relations:

Paul Burroughs

Tel.: (418) 652-8525 ext. 406

Cell.: (418) 573-8982

Fax: (418) 577-7700

E-mail: paul.burroughs@aeterna.com

#### Investor Relations:

Jacques Raymond

Tel.: (418) 652-8525 ext. 360

Cell.: (514) 703-5654

Fax: (418) 577-7700

E-mail: jacques.raymond@aeterna.com

### USA

The Investor Relations Group

Lisa Lindberg

Tel.: (212) 825-3210

Fax: (212) 825-3229

E-mail: TheProTeam@aol.com

### EUROPE

Investor relations

Matthias Seeber

Tel.: 011 49 69 4 26 02 34 25

Fax: 011 49 69 4 26 02 34 44

E-mail: matthias.seeber@zentaris.de

ATTACHED: FINANCIAL SUMMARY

AETERNA LABORATORIES INC. (TSX : AEL, NASDAQ : AELA)

### FINANCIAL SUMMARY

(in thousands of Canadian dollars, except per share data)

	THREE MONTHS ENDED DECEMBER 31	
CONSOLIDATED RESULTS	2002	2001
Unaudited	\$	\$
Revenues	28,008	20,204
Cost of sales	21,093	15,350
Selling, general and administrative	5,507	4,763
Research and development	7,782	6,209
Research tax credits and grants	(513)	(630)
Depreciation and amortization	742	615
	34,611	26,307
Operating loss	(6,603)	(6,103)

Edgar Filing: AETERNA LABORATORIES INC - Form 6-K

Interest income	973	1,065
Interest expense	(101)	(254)
-----		
LOSS BEFORE THE FOLLOWING ITEMS	(5,731)	(5,292)
Current income taxes	(792)	(640)
Future income taxes	(547)	5,674
Non-controlling interest	(940)	(2,499)
-----		
LOSS BEFORE THE GAIN ON DILUTION	(8,010)	(2,757)
Gain on dilution	-	-
-----		
NET LOSS FOR THE PERIOD	(8,010)	(2,757)
-----		
Basic and diluted loss before the gain on dilution per share	(0.20)	(0.08)
-----		
Basic and diluted net loss per share	(0.20)	(0.08)
-----		
Weighted average number of shares - Basic and diluted	40,582,591	32,505,873
-----		

CONSOLIDATED BALANCE SHEETS

-----

Cash and short-term investments  
Working capital  
Total assets  
Long-term debt  
Non-controlling interest  
Shareholders' equity  
Deficit

STOCK EXCHANGE INFORMATION AS OF DECEMBER 31, 2002

Issued and outstanding shares	40.7 MILLION
Fully diluted shares	40.8 MILLION
Market capitalization	\$241 MILLION
Average daily transactions (12 months)	37,000 SHARES

## Edgar Filing: AETERNA LABORATORIES INC - Form 6-K

ATRIUM BIOTECHNOLOGIES INC.  
 FINANCIAL SUMMARY  
 (in thousands of Canadian dollars)

	THREE MONTHS ENDED DECEMBER 31	
CONSOLIDATED RESULTS Unaudited	2002 \$	2001 \$
Revenues	27,693	20,204
Cost of sales	21,093	15,350
Selling and administrative	3,134	2,797
Research and development	278	146
Research tax credits and grants	(029)	(085)
	24,476	18,208
EBITDA	3,217	1,996
Depreciation and amortization	(112)	(204)
Interest income	240	424
Interest expense	(101)	(254)
EARNINGS BEFORE THE FOLLOWING ITEMS	3,244	1,962
Current income taxes	(792)	(335)
Future income taxes	(547)	(406)
Non-controlling interest	(343)	(080)
NET EARNINGS FOR THE PERIOD	1,562	1,141

### CONSOLIDATED BALANCE SHEETS

Cash and short-term investments  
 Working capital  
 Total assets  
 Long-term debt  
 Non-controlling interest  
 Shareholders' equity  
 Retained earnings

Edgar Filing: AETERNA LABORATORIES INC - Form 6-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AETERNA LABORATORIES INC.

DATE: FEBRUARY 20, 2003

By: /s/ CLAUDE VADBONCOEUR

-----  
Claude Vadboncoeur  
Vice President, Legal Affairs and  
Corporate Secretary